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A B S T R A C T
Introduction: Standard treatments are often unsatisfactory on chronic urticaria (CU). Acupoint
stimulation, including acupuncture, electroacupuncture, acupoint catgut embedding, acupoint injection,
has shown beneﬁt about alleviating itching, reducing amount and range of the lesions. However, the
methodological quality of these trials is unknown. Thus, the objective of this review is to evaluate the
quality and effectiveness of acupoint stimulation for chronic urticaria.
Methods: We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, CNKI, CBM,
VIP, Wanfang databases from January 1966 to June 2015. Randomized controlled trials (RCTs) on acupoint
stimulation for CU were included. The Cochrane risk of bias tool was used to evaluate methodological
quality.
Results: Eight RCTs met the inclusion criteria, which were all low quality. Acupuncture plus other
treatment was signiﬁcantly superior to western medicine alone and autologous blood injection plus
herbal medicine was better than herbal medicine alone in increasing the number of cured patients.
Conclusions: Acupoint stimulation may provide beneﬁt in CU; however, more large scale, high quality
studies are needed for assessing the effects before it is recommended.
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Urticaria (hives or wheals) is a common complaint in the
dermatology department. Urticaria is characterized by circum-
scribed itchy patches on the skin that are slightly elevated and
smooth. Lesions can be erythematous or white and change in size
and shape over a few hours or days. When urticaria persists beyond
6 weeks and recurs more than twice a week, it is deﬁned as chronic
urticaria(CU) [1,2]. Theories abound about the etiology of CU, and
were affected by many factors [2,3]. CU symptoms can be
exacerbated by physical factors such as dermatographism,
pressure, vibration, or exposure to cold, heat, or sun [1]. In most
cases, CU is self-limiting, typically lasting for months to several
years. But due to extreme pruritus, unsightly skin lesions and
symptom recurrence, quality of life is decreased [2].
The pathogenesis of CU is mast cell degranulation of mediators,
such as histamine, leukotrienes and prostaglandins [4]. Those
mediators makes ﬂuid extravasated into the superﬁcial tissues in
both the early and late-phase responses. Blood basophil immuno-
globulin E (IgE) receptor have been implicated in chronic mast cell
activation [4,5]. Itching and wealing are happened when the mast
cell component of urticaria is recognized and usually leads to
antihistamines [5].
As ﬁrst-line therapy for CU, second-generation H1-antihist-
amines are recommended by numerous guidelines and trials [5–7].
However, results of research based on such recommendation are
inconsistent, thus there is no consensus on standard treatment for
CU [8].
In China, many CU patients turned to acupuncturists for help.
Acupoint stimulation mostly means inserting needles into the
speciﬁc points in meridians [9,10]. Except for acupuncture, new
forms of acupoint stimulation, such as electroacupuncture,
acupoint injection, cutgut embedding according to traditional
Chinese theory, have been used for CU from 1965 to now. Animal
experiments have shown that acupoint stimulation can decrease
the high serum IgE level, reduce histamine and leukotrienes
secreted by mast cell, then to reduce active immune reactions and
relieve swelling and itching [11–14].
The outcomes in clinical trials [15–18] have demonstrated that
acupoint stimulation can alleviate itching, reduce amount and
range of the lesions. Disease spectrum on the use of acupuncture
has also shown that acupuncture was the second most likely
therapeutic method to treat CU in dermatology [19]. However, the
existing evidence for CU was not rigorous enough to conclude the
ﬁnding. Thus the objective of this review is to determine the
quality and effectiveness of acupoint stimulation for CU. Results of
this systematic review are shown below.
2. Methods
2.1. Systematic literature searches
We carried out electronic searches in PubMed, Embase, the
Cochrane Central Register of Controlled Trials, China National
Knowledge Infrastructure Database (CNKI), the Chongqing VIP
Chinese Science and Technology Periodical Database (VIP),
Wanfang database, and the Chinese Biomedical Literature Data-
base (CBM), with start date of January 1966 and end date of June
2015. We also hand searched a list of dermatovenereology journals
and traditional Chinese medicine journals which were not in the
electronic databases. The key words or free text words and the
searching strategies were as follows: (“urticaria” OR “hives” OR
“wheals”) AND (“acupuncture” OR “electroacupuncture” OR
“acupoint” OR “meridian” OR “auricular therapy” OR “acupoint
catgut embedding” OR “acupoint injection” OR “complementary
medicine” OR “alternative medicine”) AND (“clinical trial” OR
“randomized controlled trial”). The references of all included trials
were searched by hand. There was no language restriction.
2.2. Selection criteria
The eligible studies were identiﬁed according to the following
inclusion criteria: (1) Type of studies: randomized controlled trials
(RCTs) design; (2) Participants: patients of any age and gender
were diagnosed unequivocally as CU by explicitly diagnostic
criteria; (3) Intervention and control: intervention groups received
any acupoint stimulation including acupuncture, electroacupunc-
ture, acupoint injection and acupoint catgut embedding, combined
with or without western medication. Control groups could be no
treatment, placebo or western medication. Acupoint stimulation
with other therapies compared with the same other therapies were
also included. Therapy period and dosage were not limited; (4)
Outcomes: primary outcome should be the changes in symptoms
severity, such as changes of severity of itching, size, intensity or
duration of the lesions, the improvement of score including
Urticarial Activity Score (UAS), Itch Severity Score (ISS) and the
Total Effective Rate. We considered dermatology life quality (DLQI)
and adverse events (AEs) as the secondary outcomes.
The excluded criteria were as follow: (1) not a RCT; (2) the choice
of acupoints was not according to traditional Chinese theory; (3) the
origin of explicitly diagnostic criteria was not reported.
2.3. Data retrieval
Two reviewers (Jingdong Yan and Yuepeng An) screened the
titles and abstracts independently to identify potential eligible
articles. Then full-text articles were retrieved if necessary. If the
articles met the eligibility criteria, the data including demographic
characteristics, methodological features, treatment programs and
outcomes was extracted in predesigned data extraction form.
Disagreements were resolved by consensus with a third review
author (Ling-shu Wang).
2.4. Quality assessments
The Cochrane Collaboration’s tool for assessing risk of bias [20]
was used to assess methodological quality of the trials. The items
were: (1) random sequence generation; (2) allocation conceal-
ment; (3) blinding of participants and personnel; (4) blinding of
outcome assessment; (5) incomplete outcome data; (6) selective
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reporting; (7) other bias. We summarized the overall risk of bias
into three following categories: when all of the seven items are low
risk of bias, then it is a high-quality trial; when there is one or more
items are high risk of bias, then it is a low-quality trial; when there
is one or more items are unclear risk of bias due to insufﬁcient
information, and no high risk of bias item was found, then it is a
moderate-quality trial.
2.5. Data analysis
RevMan software (version 5.2.6) was used to analyze the data.
Relative Risk (RR) and mean difference (MD) with 95% conﬁdence
intervals (95% CI) were assessed respectively for binary data and
continuous variable data. To assess the statistical heterogeneity we
examined the I2 statistic. If I2 value  50%, we deﬁned as signiﬁcant
heterogeneity and a random-effect model was used. Otherwise,
ﬁxed-effect model was used. In addition, we check Chi square test
(Q-test) for strengthening the evidence. It was signiﬁcant
heterogeneity if P value <0.05.
Subgroup analysis was performed according to different
acupoint simulation methods in treatment groups. Funnel plot
would be used if there were 10 or more trials in the meta-analysis.
3. Results
3.1. Literature search
A total of 1292 published trials were initially identiﬁed. After
removing duplicates, 441 records were left. By screening titles and
abstracts, 369 records were excluded because they were reviews or
commentaries, basic studies or irrelevant studies. Reading the full
texts of those left, 5 trials lacked deﬁnite diagnosis criteria; 8 trials
were not real RCTs; 2 trials were duplicate published, and 49 were
case reports. Finally, 8 trials involving 755 patients satisﬁed the
inclusion criteria and were included in the meta-analysis (Fig. 1).
3.2. Trial characteristics
Characteristics of the 8 trials [21–28] were summarized in
Table 1 and Table 2. All were performed in China and published
Fig. 1. Flow chart about the review selection process.
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between 2009 and 2014. Sample size ranged from 60 to 160, and
the duration of CU was from 6 weeks to 12 years. Therapy duration
was from 20 days to 2 months. Three trials [21,23,28] used TCM
Syndrome Diagnostic efﬁcacy standards, ﬁve trials [22,24–27] used
two of Professional books for diagnosing CU (Table 3).
The intervention groups were acupoint stimulation in 1 trial
[21], acupoint stimulation combined with western medication in 6
trials [22–26,28], and acupoint stimulation combined with herbal
decoction in 1 trial [27]. Acupoint stimulation included electro-
acupuncture, acupuncture, acupoint injection, and catgut embed-
ding. The most commonly used points were Tsusanli (ST 36),
Xuehai (SP 10), Quchi (LI 11), and Sanyinjiao (SP 6). The western
medication in intervention groups or control groups were
antihistamines, in which Loratadine, Cetirizine and Epinastine
were frequently used. No trial had a blank or placebo as a control
group.
The degrees of improvement in symptoms were reported in 8
trials as the primary outcome, which was classiﬁed as cure,
markedly effective, effective and ineffective. They were all
calculated by SSRI. Once recruited into clinical study, patients
graded the score according to degree of the symptoms before and
after treatment, then doctors counted SSRI [29]. SSRI = (the score
before treatment – the score after treatment)/the score before
treatment. Cure was deﬁned as SSRI  90%; Markedly effective was
deﬁned as 60%  SSRI < 90%; Effective was deﬁned as 20%  SSRI
< 60%; Ineffective was deﬁned as SSRI < 20% [30]. The total
Table 1
Characteristics of acupoint stimulation for CU in 8 RCTs.
Author (year of publication) Sample Sex (male/
female)
Age (years) Disease duration Diagnotic criteria Baseline data comparable
Chen 2009 [21] T:30
C:30
T:12/18
C:15/15
NR NR TCM Syndrome Diagnostic Efﬁcacy
Standards
NR
Huo 2014 [22] T:80
C:80
T:42/38
C:39/41
T:32  12
C:30  13
T: 6 weeks-12 years
C: 6 weeks-12 years
Skin Venereology Yes
Lin 2012 [23] T:30
C:30
NR T:30.74  15.20
C:33.21  15.40
NR TCM Syndrome Diagnostic Efﬁcacy
Standards
NR
Liu 2012 [24] T:38
C:41
T:16/22
C:19/22
T:31.5
C:33.8
T: 1.1 years
C:1.5 years
Clinical Dermatology Yes
Wan 2013 [25] T:62
C:60
NR NR NR Skin Venereology Yes
Yu 2011 [26] T:30
C:30
T:12/18
C:14/16
T:26.87  8.57
C:26.97  8.73
T:(10.376.26)
months
C:(10.436.02)
months
Skin Venereology Yes
Zhao 2011 [27] T:58
C:50
T:38/20
C:28/22
T: 32.1  6.8
C: 30.4  8.2
T: 3 months-6 years
C: 2 months-4.8 years
Skin Venereology Yes
Zhao 2014 [28] T:57
C:49
T:29/28
C:23/26
NR T:2 months-7 years
C:3 months-8 years
TCM Syndrome Diagnostic Efﬁcacy
Standards
Yes
Abbreviations: T: intervention; C: control; NR: no reporting.
Table 2
Intervention details of acupoint stimulation for CU in 8 RCTs.
Study Intervention group Control group Duration
of
treatment
Outcome Adverse events
Chen
2009
[21]
Acupuncture at LI 11,SP 6; Electrocupuncture at SP10, ST 36;
additional points according to syndrome differentiation,
30 min, twice per week
Loratadine tablet,
10 mg, 1X/d,
4 weeks The total effective
rate
NR
Huo
2014
[22]
Acupuncture at LI 11, PC 6, SP 10, SP 6 30 minutes;Cupping
at BL 13 BL 17 for 3–5 min, and Bloodletting 2–3 ml, Once
every 2 days
Loratadine tablet,
10 mg, 1X/d,
4 weeks The total effective
rate
Yes. 3 cases in control group reported
drowsiness
Lin
2012
[23]
Acupuncture at RN 12, RN 10, RN 6, RN 4, ST 24, ST 26, SP 15
30 minutes, Moxibustion at RN8 1X/d, 5X/w
Cetirizine tablet,
10 mg, 1X/d,
4 weeks The total effective
rate; DLQI score
Yes. 1 case of faintng and 1 case of
hematoma in acupuncture group
Liu
2012
[24]
Bilaterally catgut embedding Goup1 or Group2. Group1: LI
11, SP 10, ST 36, Group2: BL 13, BL 17, BL 20, BL 25. 1X/week;
Cetirizine tablet, 10 mg, 1X/d,
Cetirizine tablet,
10 mg, 1X/d,
4 weeks The total effective
rate;Total IgE in
serum
No AEs.
Wan
2013
[25]
Acupoint injection of Huangqi extract at LI 11, ST 36, 0.5 ml
for each point, once every 2 days, a total of 10 times;
Ebastine tablet, 10 mg, 1X/d, Glycyrrhizin tablet, 75 mg, 3X/
d
Ebastine tablet,
10 mg, 1X/d;
Glycyrrhizin tablet,
75 mg, 3X/d
20 days The total effective
rate
Yes, 6 cases of fatigue in treatment group
and 8 cases of fatigue in control group.
Yu
2011
[26]
Autologous blood injection at bilateral acupoint BL 13 BL 17
LI 11 SP 10, once every 2 days, Loratadine tablet,10 mg, 1X/d
Loratadine tablet,
10 mg, 1X/d,
4 weeks The total effective
rate + DLQI
score + Recurrence
rate
Yes. 1 cases in intervention group
reported hematoma after treatment, 1
case in control group reported
drowsiness
Zhao
2011
[27]
Dang Gui Yin Zi decoction + Autologous blood injection at
ST 36, 2X/w
Dang Gui Yin Zi
decoction
8 weeks The total effective
rate + Recurrence
rate
No AEs.
Zhao
2014
[28]
Autologous blood injection 2 ml at ST 36, 2X/w; Ebastine
tablet, 10 mg, 1X/d
Ebastine tablet,
10 mg, 1X/d
2 months The total effective
rate + Recurrence
rate
NR
Abbreviations: NR: no reporting; DLQI: dermatology life quality.
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effective rate calculates formula is: The total effective rate = (
cure + markedly effective + effective)/total treatment number [30].
Two trials reported DLQI, and six trials reported AEs. Three trials
reported recurrence rates and one trial reported laboratory results.
3.3. Trial quality
According to the Cochrane risk of biases tool, all trials showed
unclear or high risk of bias, so they were all low quality (Fig. 2). All
trials claimed to have appropriate sequence generation, but details
were described only in 4 trials [21,22,24,26], in which a random
number table was used. Only one trial [21] conducted allocation
concealment. None of the trials reported blinding personnel,
blinding outcome assessment or reported the source of sample
size. One trial [24] reported the source of ﬁnancial support. No trial
reported sample size calculation.
3.4. Efﬁcacy—the total effective rate
3.4.1. Acupuncture
Two trials showed that acupuncture combined with other
treatment [22,23] were better than western medicine (RR: 1.20;
95% CI: 1.07 to 1.35; P = 0.002; 2 trials). There was no heterogeneity
among 2 trials (I2 = 0%, Chi2 P = 0.73).
3.4.2. Electroacupuncture
One trial [21] reported the improvement in symptoms of
electroacupuncture. There was no systematic difference between
electroacupuncture group and western medicine group (RR: 1.21;
95% CI: 1.00 to 1.46; P = 0.05; 1 trial).
3.4.3. Acupoint injection
Four trials reported about acupoint injection for CU. Of the four
trials, one trial [25] compared injections of Chinese medicine at
acupoints plus oral western medicine with the same western
medicine alone, two trials [26,28] compared injecting autologous
blood at acupoints plus oral western medicine with the same
western medicine alone, one trial [27] compared autologous blood
injection plus herbal medicine with the same herbal medicine alone.
The outcome showed that autologous blood injection plus herbal
medicine was superior to the same herbal medicine alone (RR: 1.30;
95% CI: 1.10 to 1.55; P = 0.002; 1 trial). But no differences were found
in injections of Chinese medicine at acupoint plus oral western
medicine compared with the same western medicine alone or
autologous blood injection plus western medicine compared with
western medicine alone (RR: 1.07; 95% CI: 0.99 to 1.17; P = 0.09; 1
trial; RR: 1.06; 95% CI: 0.98 to 1.14; P = 0.13; 2 trials).
3.4.4. Catgut embedding
One trial [24] evaluated catgut embedding for CU. The result
showed that catgut embedding combined with western medicine
was superior to western medicine alone (RR: 1.14; 95% CI: 0.98 to
1.34; P = 0.10; 1 trial).
3.5. Efﬁcacy—life quality
There were two trials reported on dermatology life quality. One
study [26] was found that autologous blood injection plus western
medicine showed a signiﬁcant improvement than western
medicine alone in life quality (MD: 0.90; 95% CI: 1.34 to
0.46; P < 0.0001;1 trial), and that was the same as in acupuncture
plus other treatment compared with western medicine [23] (MD:
1.85; 95% CI: 3.53 to 0.17; P = 0.03;1 trial).
3.6. Adverse events
Two trials [24,27] mentioned no adverse events in treatment
groups or in control groups and two trials [21,28] did not report,
the left four trials [22,23,25,26] reported adverse events. The main
syndromes were fatigue and hematoma in acupoint stimulation
plus western medicine groups, and drowsiness and fatigue in
western medicine alone groups. There were no serious adverse
events.
3.7. Publication bias
We did not perform funnel plot to assessed publication bias
since there were less than 10 trials included.
Table 3
Estimates of the total effective rate of acupoint stimulation for CU in 8 RCTs.
Author (year of publication) Comparisons Outcome estimates [95% CI] P
1. Acupuncture
1.1 Acupuncture + Other treatment versus Western medication
Huo 2014 [22] Acupuncture + Cupping + Bloodletting versus Loratadine 1.22[1.06, 1.41]
Lin 2012 [23] Acupuncture + Moxibustion versus Cetirizine 1.17[0.95, 1.43]
Overall(ﬁxed, I2 = 0%, Chi2 test P = 0.73) RR1.20[1.07, 1.35] 0.002
2. Electroacupuncture
2.1 Electroacupuncture versus Western medication
Chen 2009 [21] Electroacupuncture versus Loratadine RR1.21[1.00, 1.46] 0.05
3. Acupoint injection
3.1 Acupoint injection + Western medication versus Western medication
3.1.1 Acupoint injection + Western medication versus Western medication
Wan 2013 [25] Acupoint injection + Ebastine + Glycyrrhizin versus Ebastine + Glycyrrhizin 1.07[0.99, 1.17] 0.09
3.1.2 Autologous blood injection + Western medication versus Western medication
Yu 2011 [26] Autologous blood injection + Loratadine versus Loratadine 1.04[0.92, 1.16]
Zhao 2014 [28] Autologous blood injection + Ebastine versus Ebastine 1.07[0.98, 1.17]
Overall(ﬁxed, I2 = 0%, Chi2 test P = 0.67) RR1.06[0.98, 1.14] 0.13
3.2 Acupoint injection +Other treatment versus Other treatment
Zhao 2011 [27] Autologous blood injection + Herbal decoction versus Herbal decoction 1.30[1.10, 1.55] 0.002
4. Catgut embedding
4.1 Catgut embedding + Western medication versus Western medication
Liu 2012 [24] Catgut embedding + Cetirizine versus Cetirizine 1.14[0.98, 1.34] 0.10
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4. Discussion
This review included 8 RCTs with 755 patients. All trials
calculated the number of symptoms that improved. Acupuncture
plus other treatment was signiﬁcantly superior to western
medicine alone, and autologous blood injection plus herbal
medicine was better than herbal medicine alone in increasing
the cured patients. But more trials are needed to demonstrate the
conclusion.
This review documented Tsusanli (ST 36), Quchi (LI 11), Xuehai
(SP 10) and Sanyinjiao (SP 6) were the common acupoints being
stimulated. According to the theory of meridian and collateral,
those four acupoints could tonify qi and nourish blood to relieve
symptoms [31]. Tsusanli and Sanyinjiao were two of the frequently
used acupoints to strengthen the body resistance [32,33]. Research
showed that Quchi has a speciﬁc effect for treating urticaria
[34,35], and Xuehai can dispel wind and relieve itching [36,37].
However, some limitations of this review failed to draw a ﬁrm
conclusion. Firstly, the methodological qualities of included trials
generally needed to be improved. Only 4 trials described details of
sequence generation and only one trial report allocation conceal-
ment, indicating the likelihood that some trials were not truly
randomized, thus causing selection bias. Acupoint stimulation and
western medicine were different intervention methods and
difﬁcult to achieve blinding of patients, so it seemed important
to blind of investigator or outcome assessor, which all trials were
also failed to do. None of the trials mentioned trial registration,
thus we were not able to access the protocols to assess whether
sample size was based on the statistical power or if all outcomes
were reported. Secondly, although Pubmed, Embase, the Cochrane
Central Register of Controlled Trials were searched, all of 8 trials
were published in China, and publication bias might exist. Thirdly,
some trials showed no statistical heterogeneity, I2 is 0%, P value
was greater than 0.05, and the conﬁdence intervals overlapped.
However, there were only a few studies (one comparison have only
two trials), and each trial contained a small sample size. With more
studies the I2 value may be changed. Overall, the quality of
evidence was low in all trials, which limited us to draw a reliable
conclusion. More clinical trials with high quality and lager sample
sizes will be needed to provide credible evidence for our
conclusion.
Some patients with underlying comorbid factors (such as
hypertension) or tolerability to medications can play a role in
determining acupuncture, appropriate monitoring is important.
One review published in 2009 used subjective criteria as the
primary outcome and drew the conclusion that acupuncture was
better than western medicine for CU [38]. In our review, the total
effective rate was used as the primary outcome which came from
objective calculation of SSRI because there were no articles
reporting UAS or ISS. UAS is widely used in trials concerning the
key urticaria symptoms. The scoring system has been recom-
mended for assessment of CU activity and impact on guidelines
[39]. So we advise strongly that UAS should be used in future
studies. On the other hand, the Dermatology Life Quality Index
(DLQI), as the popular life quality index, should also be
recommended for clinical study of CU.
5. Conclusions
Based on the outcomes of meta-analyses, acupoint stimulation
seemed to be of beneﬁt for CU patients. More large scale, high
quality clinical trials based on the Consolidated Standards of
Reporting Trials (CONSORT) [40] are needed to conﬁrm the clinical
effectiveness and safety of acupoint stimulation for CU.
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